Citadel Advisors’s Structure Therapeutics GPCR Stock Holding History

Citadel Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.9M	Sell	60,100 -19,200	-24%	-$1.31M	﹤0.01%	5332
2025 Q4	$5.52M	Sell	79,300 -30,800	-28%	-$1.26M	﹤0.01%	4137
2025 Q3	$3.08M	Buy	110,100 +28,900	+36%	+$576K	﹤0.01%	5259
2025 Q2	$1.68M	Buy	81,200 +36,500	+82%	+$803K	﹤0.01%	6045
2025 Q1	$774K	Buy	44,700 +16,700	+60%	+$409K	﹤0.01%	7524
2024 Q4	$759K	Sell	28,000 -17,400	-38%	-$617K	﹤0.01%	7617
2024 Q3	$1.99M	Sell	45,400 -22,600	-33%	-$874K	﹤0.01%	5541
2024 Q2	$2.67M	Sell	68,000 -24,700	-27%	-$1.01M	﹤0.01%	4782
2024 Q1	$3.97M	Buy	92,700 +54,500	+143%	+$2.3M	﹤0.01%	4314
2023 Q4	$1.56M	Buy	+38,200	New	+$2.19M	﹤0.01%	5819

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors's GPCR Position: Q1 2026 in Review

Citadel Advisors sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 772,518 shares — an estimated $52.9M sold.

Citadel Advisors first reported a position in GPCR in Q1 2023 and held it in 12 quarters. The position peaked at $63.7M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Citadel Advisors reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 772,518 Structure Therapeutics shares in Q1 2026, an estimated $52.9M.
Citadel Advisors first reported a position in Structure Therapeutics in Q1 2023 and held it in 12 quarters.
Citadel Advisors's Structure Therapeutics position peaked at $63.7M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.